Cargando…

EGFR Target Therapy Combined with Gemox for Advanced Biliary Tract Cancers: a Meta-analysis based on RCTs

Background: Controversy exists regarding whether EGFR-targeted therapy combined with GEMOX (gemcitabine and oxaliplatin) provides additional benefits over GEMOX alone for biliary tract cancer patients. Therefore, this meta-analysis of randomized controlled trials (RCTs) was performed to assess the e...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cai, Wen, Yuan, Ying, Ge, Weiting, Fan, Yu, Liu, Xue, Wu, Dehao, Hu, Hanguang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Ivyspring International Publisher 2018
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5929093/ https://www.ncbi.nlm.nih.gov/pubmed/29721058 http://dx.doi.org/10.7150/jca.23290

Ejemplares similares

Real-World Evidence on Palliative Gemcitabine and Oxaliplatin (GemOx) Combination Chemotherapy in Advanced Biliary Tract Cancer
por: Lagenfelt, Hanna, et al.
Publicado: (2021)

Efficacy and safety of lenvatinib combined with PD-1/PD-L1 inhibitors plus Gemox chemotherapy in advanced biliary tract cancer
por: Zhu, Chengpei, et al.
Publicado: (2023)

Safety and efficacy of GEMOX plus donafenib and tislelizumab as first‐line therapy for advanced epithelial malignant biliary tract cancer
por: Wang, Longrong, et al.
Publicado: (2023)

Efficacy and safety of a triple combination of atezolizumab, bevacizumab plus GEMOX for advanced biliary tract cancer: a multicenter, single-arm, retrospective study
por: Wang, Kang, et al.
Publicado: (2023)

Camrelizumab plus gemcitabine and oxaliplatin (GEMOX) in patients with advanced biliary tract cancer: a single-arm, open-label, phase II trial
por: Chen, Xiaofeng, et al.
Publicado: (2020)

Factors Affecting the Outcomes of Patients with Malignant Rhabdoid Tumors: A Population-Based Study
por: Cai, Wen, et al.
Publicado: (2021)

A 10-year Population-based Study of the Differences between NECs and Carcinomas of the Esophagus in Terms of Clinicopathology and Survival
por: Cai, Wen, et al.
Publicado: (2019)

Immuno-genomic-radiomics to predict response of biliary tract cancer to camrelizumab plus GEMOX in a single-arm phase II trial
por: Liu, Qiu-Ping, et al.
Publicado: (2023)

A novel 4-gene prognostic signature for hypermutated colorectal cancer
por: Ge, Weiting, et al.
Publicado: (2019)

Primary tumor location (right versus left side of the colon) and resection affect the survival of patients with liver metastases from colonic neuroendocrine carcinoma: a population-based study
por: Cai, Wen, et al.
Publicado: (2021)

A Retrospective Exploration of Targeted Maintenance Therapy in Advanced Colorectal Cancer: Based on the Background of Chinese Patient Assistance Program
por: Hu, Hanguang, et al.
Publicado: (2020)

Ultra‐mutated colorectal cancer patients with POLE driver mutations exhibit distinct clinical patterns
por: Hu, Hanguang, et al.
Publicado: (2020)

Combination of anti-PD-1 antibody with P-GEMOX as a potentially effective immunochemotherapy for advanced natural killer/T cell lymphoma
por: Cai, Jun, et al.
Publicado: (2020)

Gallbladder cancer with EGFR mutation and its response to GemOx with erlotinib: a case report and review of literature
por: Soni, Kishan, et al.
Publicado: (2020)

Combination Therapies for Advanced Biliary Tract Cancer
por: Zeng, Weifeng, et al.
Publicado: (2023)

Gemcitabine and oxaliplatin (GEMOX) in gemcitabine refractory advanced pancreatic adenocarcinoma: a phase II study
por: Demols, A, et al.
Publicado: (2006)

Prolonged Complete Response after GEMOX Chemotherapy in a Patient with Advanced Fibrolamellar Hepatocellular Carcinoma
por: Gras, Pauline, et al.
Publicado: (2012)

Rectal NETs and rectosigmoid junction NETs may need to be treated differently
por: Cai, Wen, et al.
Publicado: (2019)

Combining of chemotherapy with targeted therapy for advanced biliary tract cancer: A systematic review and meta-analysis
por: Bai, Xue-Song, et al.
Publicado: (2022)

Toripalimab combined with lenvatinib and GEMOX is a promising regimen as first-line treatment for advanced intrahepatic cholangiocarcinoma: a single-center, single-arm, phase 2 study
por: Shi, Guo-Ming, et al.
Publicado: (2023)

A Retrospective Case Series Of High-Intensity Focused Ultrasound (HIFU) In Combination With Gemcitabine And Oxaliplatin (Gemox) On Treating Elderly Middle And Advanced Pancreatic Cancer
por: Tao, Shuang-fen, et al.
Publicado: (2019)

Efficacy of combined gemcitabine, oxaliplatin and pegaspargase (P-gemox regimen) in patients with newly diagnosed advanced-stage or relapsed/refractory extranodal NK/T-cell lymphoma
por: Wang, Jing-hua, et al.
Publicado: (2016)

P1174: PI3K INHIBITOR LINPERLISIB COMBINED WITH GEMCITABINE AND OXALIPATIN (GEMOX) IN RELAPSED AND/OR REFRACTORY DLBCL: ANALYSIS BASED ON TUMOR BIOLOGY
por: Zhi-Ming, LI, et al.
Publicado: (2023)

Efficacy and safety of Kanglaite plus EGFR-TKI in the treatment of advanced non-small cell lung cancer: A meta-analysis of 13 RCTs
por: Li, Dailong, et al.
Publicado: (2022)

Pattern and risk factors for distant metastases in gastrointestinal neuroendocrine neoplasms: a population‐based study
por: Cai, Wen, et al.
Publicado: (2018)

Chemoradiotherapy (Gemox Plus Helical Tomotherapy) for Unresectable Locally Advanced Pancreatic Cancer: A Phase II Study
por: Passardi, Alessandro, et al.
Publicado: (2019)

Gemcitabine-oxaliplatin (GEMOX) as salvage treatment in pretreated epithelial ovarian cancer patients
por: Vici, Patrizia, et al.
Publicado: (2013)

Immunotherapy in Advanced Biliary Tract Cancers
por: Boilève, Alice, et al.
Publicado: (2021)

Toripalimab in advanced biliary tract cancer
por: Li, Wei, et al.
Publicado: (2022)

Anti-PD-1 therapy combined with chemotherapy in patients with advanced biliary tract cancer
por: Sun, Danyang, et al.
Publicado: (2019)

Efficacy, safety, and prognostic factors of PD-1 inhibitors combined with lenvatinib and Gemox chemotherapy as first-line treatment in advanced intrahepatic cholangiocarcinoma: a multicenter real-world study
por: Zhu, Chengpei, et al.
Publicado: (2023)

Adjuvant Gemcitabine-Oxaliplatin (GEMOX) after Curative Surgery in High-risk Patients with Cholangiocarcinoma
por: Paule, Bernard, et al.
Publicado: (2010)

Nanoliposomal irinotecan in combination with leucovorin and 5-fluorouracil in advanced biliary tract cancers
por: Allo, Gabriel, et al.
Publicado: (2022)

Sequential P‐GEMOX and radiotherapy for early‐stage extranodal natural killer/T‐cell lymphoma: A multicenter study
por: Zhang, Yuchen, et al.
Publicado: (2021)

Efficacy and safety of echinocandins versus triazoles for the prophylaxis and treatment of fungal infections: a meta-analysis of RCTs
por: Wang, J.-F., et al.
Publicado: (2014)

The efficacy and safety of different pharmacological interventions for patients with advanced biliary tract cancer: A network meta-analysis
por: Sun, Xin-Fang, et al.
Publicado: (2017)

Integrative clinical and molecular analysis of advanced biliary tract cancers on immune checkpoint blockade reveals potential markers of response
por: Li, Jingjing, et al.
Publicado: (2020)

Preclinical activity of EGFR and MEK1/2 inhibitors in the treatment of biliary tract carcinoma
por: Cavalloni, Giuliana, et al.
Publicado: (2016)

Pancreatogastrostomy versus Pancreatojejunostomy: An Up-to-Date Meta-Analysis of RCTs
por: Perivoliotis, Konstantinos, et al.
Publicado: (2017)

Chemotherapy for advanced biliary tract carcinoma: A meta-analysis of randomized controlled trials
por: Chen, Lawrence, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_mufop47gj53nligr984rfdp0j7